Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (VRCA) is a clinical-stage leader in dermatology therapeutics, pioneering FDA-approved treatments for complex skin conditions. This page provides investors and healthcare professionals with essential updates on the company's advancements in medical dermatology.
Access real-time news about Verrica's clinical trials, regulatory milestones, and strategic partnerships. Our curated collection includes updates on YCANTH® (the first FDA-approved molluscum contagiosum therapy), pipeline developments like VP-315 for skin cancers, and critical business decisions affecting the dermatology sector.
Key coverage areas include FDA regulatory updates, clinical trial results, research collaborations, and market expansion strategies. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Verrica's latest developments in drug-device combination therapies and their impact on dermatological care. For comprehensive analysis of VRCA's position in medical dermatology, visit regularly for unfiltered updates directly from corporate communications and verified industry reports.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced the initiation of Part 2 of its Phase 2 clinical trial for VP-315, aimed at treating basal cell carcinoma (BCC). The first patient has been dosed, following positive outcomes from Part 1, which showed a favorable safety profile and clinical activity in higher dose ranges. This trial part seeks to optimize dosing regimens before advancing to Part 3, projected to commence in the first half of 2024. VP-315, an innovative oncolytic peptide therapy, offers a non-surgical treatment for the approximately 3-4 million BCC cases diagnosed annually in the U.S. The trial will enroll about 66 adult subjects. This advancement aligns with Verrica's focus on unmet medical needs in dermatology.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that its President and CEO, Ted White, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. The presentation, scheduled for 2:15 – 2:55 PM ET, will allow attendees to hear about Verrica's advancements in dermatology therapeutics, especially their late-stage product candidate, VP-102, aimed at treating molluscum, common warts, and external genital warts. Additionally, Verrica is developing VP-103 for plantar warts and has entered a global licensing agreement with Lytix Biopharma AS for the commercialization of VP-315. A live webcast of the event will be available on Verrica's website and will remain accessible for 30 days after the conference.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a PDUFA goal date of July 23, 2023, for its NDA of VP-102, aimed at treating molluscum contagiosum, potentially benefiting six million U.S. patients. The company raised $32.5 million in a secondary offering, providing capital to fund operations through Q1 2024. VP-315, an oncolytic peptide immunotherapy for basal cell carcinoma, is progressing to its Phase 2 trial's second part in Q2 2023. Financially, Verrica reported a net loss of $24.5 million for 2022, with reduced R&D costs and an increase in collaboration revenue to $9 million. Cash reserves stood at $34.3 million at year-end 2022.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announces that its President and CEO, Ted White, will participate in a fireside chat at The Cowen 43rd Annual Health Care Conference in Boston, MA, on March 6, 2023, from 2:50 PM to 3:20 PM ET. A live webcast of the event will be accessible via the provided link and on Verrica's website. The company is focused on dermatology therapeutics, with key products like VP-102 and VP-103 aimed at treating significant skin conditions, including warts. Verrica has also secured a worldwide license with Lytix Biopharma AS for developing VP-LTX-315 for dermatologic oncology. More details are available on their official website.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that the FDA has accepted its resubmitted New Drug Application (NDA) for VP-102, aimed at treating molluscum contagiosum, a contagious skin condition impacting around 6 million people in the U.S., mainly children.
The assigned PDUFA goal date is July 23, 2023. VP-102 is designed for targeted delivery of cantharidin, and positive results from two Phase 3 trials support its efficacy and safety. The drug could potentially be the first approved treatment for molluscum contagiosum, meeting a significant unmet medical need.
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) has priced an underwritten offering of 750,000 shares of common stock at $6.75 each and pre-funded warrants for 4,064,814 shares at $6.7499 each, aiming for gross proceeds of approximately $32.5 million. The offering, led by a healthcare dedicated fund, is anticipated to close by February 23, 2023, subject to customary conditions. Jefferies LLC is the sole book-runner. The offering is part of a previously effective shelf registration statement filed with the SEC.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has resubmitted the New Drug Application (NDA) for VP-102, aiming to become the first FDA-approved treatment for molluscum contagiosum, affecting over 6 million patients in the U.S., primarily children. This resubmission addresses previous deficiencies highlighted in the Complete Response Letter received last year. VP-102, a topical drug-device combination with 0.7% cantharidin, is designed for precise application. The company also completed Phase 2 studies for treating common and external genital warts. If approved, VP-102 may be marketed as YCANTH™.
